Research progress on the treatment of ischemia-reperfusion injury with human umbilical cord mesenchymal stem cells and their derivatives
10.12464/j.issn.1674-7445.2025075
- VernacularTitle:人脐带间充质干细胞及其衍生物治疗缺血-再灌注损伤的研究进展
- Author:
Ru NIE
1
,
2
,
3
;
Yunlong DUAN
1
,
3
;
Mingquan PANG
3
;
Zhixin WANG
3
;
Haining FAN
3
Author Information
1. Clinical Medical College of Qinghai University, Xining 810000, China
2.
3. .
- Publication Type:TransplantationForefront
- Keywords:
Human umbilical cord mesenchymal stem cell;
Ischemia-reperfusion injury;
Exosome;
Extracellular vesicle;
Mesenchymal stem cell;
Apoptosis;
Mitochondrial function;
Oxidative stress
- From:
Organ Transplantation
2025;16(4):516-525
- CountryChina
- Language:Chinese
-
Abstract:
Ischemia-reperfusion injury (IRI) can lead to organ dysfunction and tissue necrosis in the liver, kidney, myocardium and spinal cord, and there is currently a lack of effective treatment options. Human umbilical cord mesenchymal stem cell (HUC-MSC) and their derivatives have anti-inflammatory, anti-apoptotic, reactive oxygen species scavenging, mitochondrial and endothelial function improvement properties, and are ideal gene therapy carrier cells, providing new possibilities for the treatment of IRI in different organs. This article reviews the concept and mechanisms of IRI, the biological characteristics of HUC-MSC and their derivatives and their comparison with mesenchymal stem cells from other sources, and the mechanisms of HUC-MSC in treating IRI in different organs. It also summarizes and analyzes the advantages and disadvantages of HUC-MSC in protecting different organs from IRI, and prospects future research directions to explore more valuable research paths.
